Clinically, antibodies blocking PD-1/PD-L1 axis reinvigorate the exhausted T cells in tumor microenvironment (TME) and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as lymphoma and melanoma.13,14 However, not all patients respond to PD-1 monotherapy and there is considerable interest in developing combination therapy to improve the overall response rate and trigger more complete and durable response in patients with cancer. This evidence concerns the gene CD274 and cancer.